As a new oral glucose-lowering agent, SGLT2 inhibitor can significantly reduce the levels of fasting plasma glucose and HbA1c, and alleviate the endothelial damage caused by persistent hyperglycemia (62). The gene discussed is SLC5A2; the disease is Hyperglycemia.